HALO · Halozyme Therapeutics, Inc. · Webcasts, Transcripts & Audio
$100.27
-0.40 (-0.40%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$11.43B
Shares
114.01M
Volume · Nov 13
2.28M
Avg daily vol (3M)
2.24M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Halozyme Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Halozyme Therapeutics, Inc. (HALO), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-05
Halozyme Therapeutics, Inc. (HALO) Q3 2026 Earnings Call Transcript
Confident tone
EP622 patent litigation
Hyperconcentration technologies
Royalty and revenue growth
Revenue
$492.97M
▲ 39.2% YoY Diluted EPS
$2.01
▲ 40.6% YoY Gross margin
83.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-16
Halozyme Therapeutics, Inc. (HALO) September 16, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-15
Halozyme Therapeutics, Inc. (HALO) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Halozyme Therapeutics, Inc. (HALO) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Halozyme Therapeutics, Inc. (HALO) Q2 2026 Earnings Call Transcript
Confident tone
Royalty revenue growth and diversification
Litigation and IP risk (Merck/LTAGE patent dispute)
M&A and capital allocation
Revenue
$481.00M
▲ 47.7% YoY Diluted EPS
$1.90
▲ 42.9% YoY Gross margin
83.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-11
Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript
Confident tone
Hypercon platform progress and partnerships
2029-plus revenue drivers and pipeline expansion
Subcutaneous PK pathway and regulatory risk
Revenue
$376.71M
▲ 42.2% YoY Diluted EPS
$1.22
▲ 31.2% YoY Gross margin
79.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-01-28
Halozyme Therapeutics, Inc. (HALO) January 28, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-01-28
Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript
Confident tone
Strategic Acquisitions and Platform Expansion
ENHANZE Royalty Growth
Newly Launched Subcutaneous Products
Revenue
$451.77M*
▲ 51.6% YoY Gross margin
82.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Halozyme Therapeutics, Inc. (HALO) Q3 2025 Earnings Call Transcript
Confident tone
ENHANZE drug delivery technology
Elektrofi acquisition and Hypercon technology
Growth catalysts and milestones
Revenue
$354.26M
▲ 22.1% YoY Diluted EPS
$1.43
▲ 36.2% YoY Gross margin
84.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Halozyme Therapeutics, Inc. (HALO) Q2 2025 Earnings Call Transcript
Confident tone
Merck Patent Litigation
Royalty Revenue Growth
DARZALEX Subcutaneous
Revenue
$325.72M
▲ 40.8% YoY Diluted EPS
$1.33
▲ 84.7% YoY Gross margin
85.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Halozyme Therapeutics, Inc. (HALO) Q1 2025 Earnings Call Transcript
Confident tone
ENHANZE blockbusters (DARZALEX, Phesgo, VYVGART Hytrulo)
Litigation (Merck/Keytruda, MDASE, PGR)
M&A and inorganic growth
Revenue
$264.86M
▲ 35.2% YoY Diluted EPS
$0.93
▲ 55% YoY Gross margin
81.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-18
Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript
Confident tone
Record 2024 financial performance
New target nominations and pipeline expansion
VYVGART Hytrulo and CIDP expansion
Revenue
$298.01M*
▲ 29.5% YoY Gross margin
85.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2025-01-08
Halozyme Therapeutics, Inc. (HALO) January 8, 2025 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY24 · Q3
2024-10-31
Halozyme Therapeutics, Inc. (HALO) Q3 2024 Earnings Call Transcript
Confident tone
ENHANZE royalty growth and partner approvals
MDASE / modified hyaluronidase IP licensing
New target nominations and deal expansion
Revenue
$290.08M
▲ 34.3% YoY Diluted EPS
$1.05
▲ 72.1% YoY Gross margin
83.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Halozyme Therapeutics, Inc. (HALO) Q2 2024 Earnings Call Transcript
Confident tone
Wave 3 Product Approvals and Pipeline Progress
Collaboration and Milestone Revenue Cadence
Capital Allocation and M&A / Business Development
Revenue
$231.35M
▲ 4.7% YoY Diluted EPS
$0.72
▲ 28.6% YoY Gross margin
82.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Halozyme Therapeutics, Inc. (HALO) Q1 2024 Earnings Call Transcript
Confident tone
ENHANZE platform and high-volume auto-injector
Partner product approvals and launches
Regulatory progress and PDUFA dates
Revenue
$195.88M
▲ 20.8% YoY Diluted EPS
$0.60
▲ 106.9% YoY Gross margin
85.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-20
Halozyme Therapeutics, Inc. (HALO) Q4 2023 Earnings Call Transcript
Confident tone
ENHANZE pipeline expansion and Wave 3 readouts
Royalty revenue growth from key partnered products
FY2024 guidance and five-year financial outlook
Revenue
$230.04M*
▲ 26.7% YoY Gross margin
77.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Call Transcript
Revenue
$216.03M
▲ 3.4% YoY Diluted EPS
$0.61
▲ 38.6% YoY Gross margin
74.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Halozyme Therapeutics, Inc. (HALO) Q2 2023 Earnings Call Transcript
Revenue
$221.04M
▲ 45.1% YoY Diluted EPS
$0.56
▲ 250% YoY Gross margin
77.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Halozyme Therapeutics, Inc. (HALO) Q1 2023 Earnings Call Transcript
Revenue
$162.14M
▲ 38.3% YoY Diluted EPS
$0.29
▼ 32.6% YoY Gross margin
78.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-21
Halozyme Therapeutics, Inc. (HALO) Q4 2022 Earnings Call Transcript
Revenue
$181.50M*
▲ 77.9% YoY Gross margin
76.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Halozyme Therapeutics, Inc. (HALO) Q3 2022 Earnings Call Transcript
Revenue
$208.98M
▲ 80.4% YoY Diluted EPS
$0.44
▼ 70.3% YoY Gross margin
77.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Halozyme Therapeutics, Inc. (HALO) Q2 2022 Earnings Call Transcript
Revenue
$152.37M
▲ 11.7% YoY Diluted EPS
$0.16
▼ 74.2% YoY Gross margin
77.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Halozyme Therapeutics, Inc. (HALO) Q1 2022 Earnings Call Transcript
Revenue
$117.28M
▲ 31.7% YoY Diluted EPS
$0.43
▲ 126.3% YoY Gross margin
86.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-22
Halozyme Therapeutics, Inc. (HALO) Q4 2021 Earnings Call Transcript
Revenue
$102.00M*
▼ 16.2% YoY Gross margin
78.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Halozyme Therapeutics, Inc. (HALO) Q3 2021 Earnings Call Transcript
Revenue
$115.83M
▲ 77.3% YoY Diluted EPS
$1.48
▲ 492% YoY Gross margin
84.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Halozyme Therapeutics, Inc. (HALO) Q2 2021 Earnings Call Transcript
Revenue
$136.46M
▲ 147.1% YoY Diluted EPS
$0.62
▲ 226.3% YoY Gross margin
83.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Halozyme Therapeutics, Inc. (HALO) Q1 2021 Earnings Call Transcript
Revenue
$89.02M
▲ 251.1% YoY Diluted EPS
$0.19
Gross margin
79.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-23
Halozyme Therapeutics, Inc. (HALO) Q4 2020 Earnings Call Transcript
Revenue
$121.70M
▲ 126.8% YoY Diluted EPS
$0.50
Gross margin
5.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-02
Halozyme Therapeutics, Inc. (HALO) Q3 2020 Earnings Call Transcript
Revenue
$65.32M
▲ 41.3% YoY Diluted EPS
$0.25
Gross margin
5.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Halozyme Therapeutics, Inc. (HALO) Q2 2020 Earnings Call Transcript
Revenue
$55.22M
▲ 41.1% YoY Diluted EPS
$0.19
Gross margin
1.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Halozyme Therapeutics, Inc. (HALO) Q1 2020 Earnings Call Transcript
Revenue
$25.35M
▼ 55.5% YoY Diluted EPS
$-0.04
▼ 500% YoY Gross margin
9.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-24
Halozyme Therapeutics, Inc. (HALO) Q4 2019 Earnings Call
Revenue
$53.66M
▼ 10.9% YoY Diluted EPS
$-0.24
Gross margin
11.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–33 of 33 webcasts
Key facts
CIK
1159036
CUSIP
40637H109
13F (30d)
619 filings
569 filers
Visit website
Investor relations